For laboratory research use only. Not for human or veterinary use.

Demonstration data. Every lot code, purity figure, chromatogram, certificate, laboratory and date on this site is a sample for design review. None of it is a real measurement.
Skip to content
QualityVerifyResearch CenterWholesaleAboutPartner with usSupportContact Shop

Tesamorelin

A GHRH-analogue peptide. Tesamorelin is the active ingredient in an FDA-approved pharmaceutical product for a specific indication; NuePharma's material is a separate, unapproved research-use item.

Research Article Compound Hubs 2 min read

Mechanism

A hormone-release pathway, one step at a time

Tesamorelin is a synthetic analogue of a hormone the body already makes. This is the sequence that follows, one step at a time.

Step 1 GHRH analogue

Tesamorelin

An analogue is a laboratory-made copy of a molecule the body already makes, built to behave like it.Schematic diagram: a peptide backbone drawn as beads on a curve, labelled Tesamorelin, a synthetic analogue of growth-hormone-releasing hormone. The drawing is a schematic and does not depict a molecular structure.CompoundMade in the labTesamorelinA synthetic analogue of GHRH
An analogue is a laboratory-made copy of a molecule the body already makes, built to behave like it. Hold any part of the figure to follow its route Press and hold any part of the figure to follow its route Schematic backbone. Bead count is illustrative. This is not a structural depiction.

What you're seeing

A laboratory-made copy of growth-hormone-releasing hormone (GHRH), the signal the brain normally sends to the pituitary gland.

Scientific detail

A synthetic analogue of growth hormone-releasing factor. The FDA labeling for the approved pharmaceutical product states it binds and stimulates human GRF receptors with similar potency to the endogenous hormone. An analogue is a modified copy of a natural molecule, built to behave like it.

Terminology What is a peptide, and how is it different from a protein? What are receptors, ligands, agonists, and antagonists?

Source EGRIFTA WR (tesamorelin) prescribing information — U.S. Food & Drug Administration Tesamorelin — LiverTox, NCBI Bookshelf (National Institutes of Health)

Step 2 The pituitary gland

Where this happens

The pituitary is a small gland at the base of the brain. That is where this sequence starts.Orientation diagram: a simplified cranial outline with the brain inside it and the brainstem descending. The pituitary gland is marked as a small node at the base of the brain, labelled with the somatotroph cells it contains, and a curved arrow marks the GHRH signal arriving there from the brain above.Where this happensGHRHPituitary glandSomatotroph cells
The pituitary is a small gland at the base of the brain. That is where this sequence starts. A simplified orientation figure, not an anatomical illustration and not to scale. It marks where the cited sources place the receptor; it does not depict a person.

What you're seeing

The pituitary is a small gland at the base of the brain. The signal the brain sends acts there, on the cells that make growth hormone.

Scientific detail

The cited labeling states that GHRH acts on pituitary somatotroph cells to stimulate the synthesis and pulsatile release of endogenous growth hormone, and the LiverTox entry states that tesamorelin activates GHRH receptors in the pituitary. The figure is a simplified orientation drawing of that location — not an anatomical illustration, and not to scale.

Terminology What are receptors, ligands, agonists, and antagonists?

Source EGRIFTA WR (tesamorelin) prescribing information — U.S. Food & Drug Administration Tesamorelin — LiverTox, NCBI Bookshelf (National Institutes of Health)

Step 3 Pituitary somatotrophs

GHRH receptor

The GHRH receptor is the receiving point. Binding it is what starts the sequence — nothing further happens without this step.Schematic diagram: tesamorelin, drawn as a short peptide, arrives at a seven-transmembrane GHRH receptor set in a cell membrane, and a signal passes from the receptor into the cell below.ExtracellularIntracellularPituitary glandTesamorelinGHRH receptorReceptor activated
The GHRH receptor is the receiving point. Binding it is what starts the sequence — nothing further happens without this step.

What you're seeing

The receiving point on the cells of the pituitary gland. Binding it is the step that starts everything downstream.

Scientific detail

The FDA labeling for the approved pharmaceutical product states that tesamorelin binds and stimulates human GRF receptors with potency similar to the endogenous hormone. The receptor sits on pituitary somatotroph cells; nothing further in this sequence happens without this step.

Terminology What are receptors, ligands, agonists, and antagonists?

Source EGRIFTA WR (tesamorelin) prescribing information — U.S. Food & Drug Administration Tesamorelin — LiverTox, NCBI Bookshelf (National Institutes of Health)

Step 4 Inside the somatotroph

Pituitary signaling

The cited labeling describes release as pulsatile — in bursts. That is why this is studied as a release pathway rather than as hormone replacement.Schematic diagram: inside a pituitary somatotroph cell, an activated receptor at the upper membrane sends a signal downward; growth hormone is synthesised and then released from the lower membrane in three separate bursts rather than continuously.Pituitary somatotrophPituitary glandGHRH receptor activatedGrowth hormone synthesisedReleased in pulses, not at a constant level
The cited labeling describes release as pulsatile — in bursts. That is why this is studied as a release pathway rather than as hormone replacement.

What you're seeing

Once the receptor is activated, the pituitary cell makes growth hormone and releases it in bursts rather than at a constant level.

Scientific detail

GHRH acts on pituitary somatotroph cells to stimulate the synthesis and pulsatile release of endogenous growth hormone. "Pulsatile" matters: the pathway works in bursts rather than a steady level, which is part of why it is studied as a release pathway rather than a hormone replacement.

Terminology What are receptors, ligands, agonists, and antagonists?

Source EGRIFTA WR (tesamorelin) prescribing information — U.S. Food & Drug Administration Tesamorelin — LiverTox, NCBI Bookshelf (National Institutes of Health)

Step 5 Released by the pituitary

Growth hormone

Growth hormone acts on many tissues at once. The figure shows where it acts; it does not describe a result in a person.Schematic diagram: growth hormone leaves the pituitary, travels in the blood, and reaches four named tissue types — liver cells, muscle cells, bone and cartilage, and fat cells.PathwayBloodstreamGrowth hormonecarried in the bloodLiver cellsMuscle cellsBone and cartilageFat cells
Growth hormone acts on many tissues at once. The figure shows where it acts; it does not describe a result in a person. Tissues named in the cited labeling. The figure shows where the signal acts, not what it produces in a person.

What you're seeing

The hormone the pituitary releases in response. It travels in the blood and acts on many different tissues.

Scientific detail

Growth hormone interacts with receptors on a range of target cells, including hepatocytes, myocytes, osteoblasts, chondrocytes and adipocytes. Some, but not all, of its effects are mediated by IGF-1. The labeling reports no clinically significant change in other pituitary hormones such as TSH, LH, ACTH or prolactin.

Terminology What do pharmacology, pharmacokinetics, and pharmacodynamics mean?

Source EGRIFTA WR (tesamorelin) prescribing information — U.S. Food & Drug Administration Tesamorelin — LiverTox, NCBI Bookshelf (National Institutes of Health)

Step 6 Produced largely in the liver

IGF-1

IGF-1 is one of the ways growth hormone has its effects — not the only one. The dashed branch is that distinction, drawn rather than omitted.Schematic diagram: growth hormone reaches liver cells, which produce IGF-1. A separate dashed branch bypasses the liver, marking that some growth-hormone effects are not mediated by IGF-1.DownstreamLiverGrowth hormoneLiver cellsproducesIGF-1
IGF-1 is one of the ways growth hormone has its effects — not the only one. The dashed branch is that distinction, drawn rather than omitted. Dashed line: some of growth hormone's effects are not mediated by IGF-1. Measuring a change in this axis is not the same as demonstrating a clinical benefit.

What you're seeing

Insulin-like growth factor 1. Growth hormone prompts the liver to produce it, and it is one of the ways growth hormone has its effects.

Scientific detail

Growth hormone stimulates IGF-1 production in hepatocytes and peripheral tissues; the labeling reports that tesamorelin increases IGF-1 and IGFBP-3 levels. Together the GH/IGF-1 axis is a well-characterised regulatory pathway. Measuring a change in this axis is not the same as demonstrating a clinical benefit, which is what a trial for a specific indication establishes.

Terminology What do pharmacology, pharmacokinetics, and pharmacodynamics mean?

Source EGRIFTA WR (tesamorelin) prescribing information — U.S. Food & Drug Administration Tesamorelin — LiverTox, NCBI Bookshelf (National Institutes of Health)

That is the mechanism in brief. The rest of this page is the detail.

View Tesamorelin Verify a lot

Keep going

Go deeper into the science.

Discover the compounds, pathways and research systems connected to what you're already exploring.

Related research

  • Ipamorelin

    For research use only. Not for human consumption.

    10 mg $109.00

    Two receptor routes into growth-hormone release — the GHRH receptor and the ghrelin receptor — studied as separate entry points to the same axis.

    Explore the science View product

Adjacent research pathways

  • Retatrutide

    For research use only. Not for human consumption.

    15 mg $189.00

    Explore incretin and glucagon-receptor research, a separate part of the metabolic and endocrine picture.

    Explore the science View product

Research systems Endocrine signaling Metabolic pathways

These are separate research materials with separate research records. Nothing here suggests combining them, and no connection above is a claim about using more than one.

Simplified pathway, drawn for educational purposes. It shows what published research describes about the molecule. It does not describe a result in a person, and it is not a claim about NuePharma material.

What research has established

  1. Preclinical research Published

    The receptor pharmacology is characterised in the approved product's own labeling: tesamorelin binds and stimulates human GRF receptors with potency similar to the hormone the body makes, and the GH/IGF-1 axis it feeds into is a long-established pathway.

    Source EGRIFTA WR (tesamorelin) prescribing information — U.S. Food & Drug Administration Tesamorelin — LiverTox, NCBI Bookshelf (National Institutes of Health)

  2. Human research Published

    Clinical trials in adults with HIV-associated lipodystrophy supported the original approval, and the labeling reports increases in IGF-1 and IGFBP-3 without clinically significant change in other pituitary hormones. Research outside that specific population is a separate question from what those trials established.

    Source EGRIFTA WR (tesamorelin) prescribing information — U.S. Food & Drug Administration EGRIFTA SV (tesamorelin for injection) prescribing information — U.S. Food & Drug Administration FDA approval letter, Egrifta (tesamorelin), 2010

  3. Regulatory status Approved, separately

    An FDA-approved pharmaceutical product containing tesamorelin exists, for one narrow indication. NuePharma's material is not that product and carries none of that approval. See the note below.

    Source EGRIFTA WR (tesamorelin) prescribing information — U.S. Food & Drug Administration FDA approval letter, Egrifta (tesamorelin), 2010

Tesamorelin is the active ingredient in an FDA-approved pharmaceutical product, approved for one specific indication: reduction of excess visceral abdominal fat in adults with HIV-associated lipodystrophy. NuePharma's tesamorelin is an unapproved research-use material. It is not that product, is not manufactured or distributed under that approval, and carries none of its regulatory status.

Sources for this diagram

  1. EGRIFTA WR (tesamorelin) prescribing information — U.S. Food & Drug Administration
  2. EGRIFTA SV (tesamorelin for injection) prescribing information — U.S. Food & Drug Administration
  3. FDA approval letter, Egrifta (tesamorelin), 2010
  4. Tesamorelin — LiverTox, NCBI Bookshelf (National Institutes of Health)

Overview. Tesamorelin is a synthetic peptide analogue of growth hormone-releasing hormone (GHRH). It is an important case where the distinction between “an FDA-approved pharmaceutical product exists” and “NuePharma’s research material is that product” genuinely matters, so it is stated plainly here.

Molecule / class. Tesamorelin is a GHRH analogue — a synthetic peptide engineered to mimic the activity of naturally occurring growth hormone-releasing hormone.

Mechanism under investigation. GHRH acts on the GHRH receptor, primarily in the pituitary gland, to stimulate the release of growth hormone (GH). Growth hormone in turn stimulates production of insulin-like growth factor 1 (IGF-1), largely in the liver; together, the GH/IGF-1 axis is a well-studied regulatory pathway involved in metabolism and body composition, among other functions.

Why the pathway is researched. Because the GH/IGF-1 axis affects fat and lean tissue distribution and metabolism broadly, GHRH analogues have been studied for conditions involving abnormal fat distribution and for other GH-axis-related research questions.

Regulatory status — read carefully. Tesamorelin is the active ingredient in an FDA-approved pharmaceutical product (marketed as EGRIFTA and its later formulations). That approval is for a specific, narrow indication: the reduction of excess visceral abdominal fat in HIV-infected adult patients with lipodystrophy, first approved in 2010 based on clinical trials in patients with that specific condition. It is not approved for general or cosmetic use, and is not approved for use in people without that diagnosis.

NuePharma’s material is not that approved product. NuePharma’s Tesamorelin listing is an unapproved research-use material, supplied for laboratory research only — not the approved pharmaceutical product, not manufactured or distributed under that product’s approval, and not intended for the approved product’s clinical use or any other human or veterinary use. The existence of an approved indication for tesamorelin as a molecule does not extend any approval to this research material.

What remains unknown, in a research context. Effects and safety profiles outside the specific approved population and indication are a separate, ongoing research question from what supported the original approval.

NuePharma product information. NuePharma’s Tesamorelin listing is 20 mg per vial, supplied lyophilized, for research use only.

Sources & further reading

Verify a lot

Related

Back to the Research Center

Back to the product

Every unit of this compound traces to a lot, and every lot to its own analytical record.

View Tesamorelin Verify a lot

Can't find your answer?

Order / product / documentation

support@nuepharmahealth.com

Contact support

Wholesale

Wholesale inquiry

Business / media / creator / partnerships

hello@nuepharmahealth.com

Contact NuePharma

Verify

Verify a lot